Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Nano CD5-CAR T Cells for Relapsed/Refractory T-ALL/LBL
NCT07678307Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of autologous nano CD5-CAR T cells in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
autologous nano CD5-CAR T cells
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07678307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678307.